Literature DB >> 27912145

Chloroquine (CQ) exerts anti-breast cancer through modulating microenvironment and inducing apoptosis.

Yanjun Zhang1, Yu Cao2, Xiaodan Sun3, Yonghui Feng4, Yunting Du3, Fei Liu3, Chunyun Yu1, Feng Jin5.   

Abstract

CQ is an anti-malaria drug, which has been used for years. However, there are published articles about its activity in anti-cancers. The aim of this approach was to look at possibility and related mechanisms of anti-breast cancer (mouse breast cancer cell line 4T1) by CQ alone. The studies of anti 4T1 in vitro and in vivo by CQ were performed. The growth of 4T1 in vitro and in vivo, survival of mice post treatment with CQ, changes of immune parameters and microenvironment in mice were evaluated. Our results demonstrate that CQ could markedly inhibit growth of 4T1 in vitro through inducing apoptosis of cells, inhibiting secretion of TGF-β and prolong the mice survival in vivo through boosting immune system by upregulating CD8+ T cell, and through down-regulating tumor associated macrophages (TAM), myeloid derived suppressing cells (MDSC) and Tregs, in microenvironment of mice bearing tumor. This provides a new mode of action for CQ and it is therefore concluded that CQ could be with potential in breast cancer therapy.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Breast cancer; Chloroquine; Immunoregulation; Tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27912145     DOI: 10.1016/j.intimp.2016.11.027

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

Review 1.  Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways.

Authors:  Lokman Varisli; Osman Cen; Spiros Vlahopoulos
Journal:  Immunology       Date:  2019-12-22       Impact factor: 7.397

2.  A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity.

Authors:  Katerina N Panagiotaki; Zili Sideratou; Spiros A Vlahopoulos; Maria Paravatou-Petsotas; Michael Zachariadis; Nikolas Khoury; Vassilis Zoumpourlis; Dimitris Tsiourvas
Journal:  Pharmaceuticals (Basel)       Date:  2017-11-21

3.  Combination of Detoxified Pneumolysin Derivative ΔA146Ply and Berbamine as a Treatment Approach for Breast Cancer.

Authors:  Hong Zhang; Tao Zhu; Ruoqiu Fu; Yang Peng; Peng Jing; Wenchun Xu; Hong Wang; Sijie Li; Zhaoche Shu; Yibing Yin; Xuemei Zhang
Journal:  Mol Ther Oncolytics       Date:  2020-06-24       Impact factor: 7.200

4.  Hemozoin-induced activation of human monocytes toward M2-like phenotype is partially reversed by antimalarial drugs-chloroquine and artemisinin.

Authors:  Deepali Bobade; Ashwin V Khandare; Mangesh Deval; Padma Shastry; Prakash Deshpande
Journal:  Microbiologyopen       Date:  2018-06-07       Impact factor: 3.139

Review 5.  Molecular Repolarisation of Tumour-Associated Macrophages.

Authors:  Floris J van Dalen; Marleen H M E van Stevendaal; Felix L Fennemann; Martijn Verdoes; Olga Ilina
Journal:  Molecules       Date:  2018-12-20       Impact factor: 4.411

Review 6.  Hydroxychloroquine in rheumatic autoimmune disorders and beyond.

Authors:  Eliise Laura Nirk; Fulvio Reggiori; Mario Mauthe
Journal:  EMBO Mol Med       Date:  2020-07-26       Impact factor: 12.137

7.  Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation.

Authors:  Ji-Hyang Kim; Hack-Sun Choi; Dong-Sun Lee
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

Review 8.  Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.

Authors:  Haoyang Huang; Qing He; Binghua Guo; Xudong Xu; Yinjuan Wu; Xuerong Li
Journal:  Drug Des Devel Ther       Date:  2021-06-22       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.